- Pivotal, double-blind, controlled
phase III clinical trial involved patients receiving highly emetogenic chemotherapy.
EFFECTIVE CINV PREVENTION1,2
- ASCO and NCCN antiemetic guidelines
recommend a 5-HT3 receptor antagonist combined with a corticosteroid for patients
receiving highly emetogenic chemotherapy.3,4
*97.5% CI and two-sided Fisher's exact test (significance level=0.025) indicate a
difference between ALOXI® and ondansetron.
†Intent-to-treat cohort.
- 82% of patients received high-dose
cisplatin (
60
mg/m2). Other agents included cyclophosphamide (>1500 mg/m2) and dacarbazine.1,2
MORE PATIENTS WITH NO EMESIS1
- Overall, significantly more patients
were emesis-free after receiving ALOXI than after ondansetron (p=0.013).1
*p
0.05 for ALOXI 0.25 mg vs ondansetron (Chi-Square test).
†Intent-to-treat cohort.
References
- Rugo HS, Grunberg SM. Single-dose palonosetron is superior to single-dose ondansetron
or dolasetron in preventing emesis in patients receiving highly emetogenic chemotherapy
(HEC) or anthracycline-cyclophosphamide (AC)-based chemotherapy for breast cancer
[abstract]. J Support Oncol 2005;3(suppl 3):26. Abstract PA-13.
- Aapro MS, Bertoli L, Lordick F, Bogdanova NV, Macciocchi A. Palonosetron (PALO)
is effective is preventing acute and delayed chemotherapy-induced nausea and vomiting
(CINV) in patients receiving highly emetogenic chemotherapy (HEC). Support Care
Cancer. 2003;11:391. Abstract A-17.
- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology:
Antiemesis. Version 1.2004: AE-2.
- Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics:
evidence-based, clinical practice guidelines. American Society of Clinical Oncology.
J Clin Oncol. 1999;17:2971-2994.